Oculis (NASDAQ:OCS) Stock Price Up 8.3%

Oculis Holding AG (NASDAQ:OCS)’s stock price rose 8.3% on Monday . The stock traded as high as $13.16 and last traded at $13.02. Approximately 82,027 shares changed hands during trading, an increase of 74% from the average daily volume of 47,052 shares. The stock had previously closed at $12.02.

Analysts Set New Price Targets

A number of equities analysts have commented on OCS shares. Robert W. Baird lowered their price objective on Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 19th. Wedbush reaffirmed an “outperform” rating and set a $29.00 target price on shares of Oculis in a report on Wednesday, March 6th. Chardan Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of Oculis in a report on Tuesday, March 19th. Finally, HC Wainwright cut their target price on Oculis from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, April 24th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Oculis presently has an average rating of “Buy” and an average target price of $29.14.

Oculis Price Performance

The company has a quick ratio of 5.29, a current ratio of 5.29 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average price of $11.85 and a 200-day moving average price of $11.24.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Monday, March 18th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.04. The firm had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.28 million. Analysts anticipate that Oculis Holding AG will post -1.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oculis

Institutional investors have recently bought and sold shares of the company. Wolverine Asset Management LLC purchased a new stake in shares of Oculis in the third quarter worth $77,000. Searle & CO. bought a new position in Oculis in the fourth quarter valued at $112,000. Compagnie Lombard Odier SCmA increased its stake in Oculis by 47.3% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock valued at $1,053,000 after acquiring an additional 30,750 shares during the last quarter. Finally, abrdn plc bought a new position in Oculis in the fourth quarter valued at $15,980,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.